[HTML][HTML] Updated results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed …
F Morschhauser, I Flinn, RH Advani, CS Diefenbach… - Blood, 2014 - Elsevier
Background: Previously reported results from an ongoing study of polatuzumab vedotin
(PoV) and pinatuzumab vedotin (PiV), antibody drug conjugates (ADC) containing the anti-
mitotic MMAE targeting CD79b (PoV) and CD22 (PiV), showed clinical activity in
combination with rituximab (R) in relapsed/refractory (r/r) diffuse large B-cell lymphoma
(DLBCL) and follicular lymphoma (FL). Here we report updated results of ADC+ R at the
RP2D of 2.4 mg/kg and initial results of PoV+ R in r/r FL at the PoV dose of 1.8 mg/kg …
(PoV) and pinatuzumab vedotin (PiV), antibody drug conjugates (ADC) containing the anti-
mitotic MMAE targeting CD79b (PoV) and CD22 (PiV), showed clinical activity in
combination with rituximab (R) in relapsed/refractory (r/r) diffuse large B-cell lymphoma
(DLBCL) and follicular lymphoma (FL). Here we report updated results of ADC+ R at the
RP2D of 2.4 mg/kg and initial results of PoV+ R in r/r FL at the PoV dose of 1.8 mg/kg …
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with …
F Morschhauser, I Flinn, RH Advani, LH Sehn… - 2014 - ascopubs.org
8519 Background: PoV and PiV, antibody drug conjugates (ADC) containing the anti-mitotic
MMAE targeting CD79b (PoV) and CD22 (PiV), showed clinical activity in Phase I. The
current study aims to compare PoV and PiV+ RTX in R/R DLBCL and R/R follicular
lymphoma (FL). Methods: Pts were randomized to receive PoV or PiV+ RTX (ADC 2.4
mg/kg+ RTX 375 mg/m2) every 21 days. Tumor assessments were performed every 3
months. Results: As of 8 November 2013, 58 received PoV+ RTX (38 DLBCL; 20 FL), 63 …
MMAE targeting CD79b (PoV) and CD22 (PiV), showed clinical activity in Phase I. The
current study aims to compare PoV and PiV+ RTX in R/R DLBCL and R/R follicular
lymphoma (FL). Methods: Pts were randomized to receive PoV or PiV+ RTX (ADC 2.4
mg/kg+ RTX 375 mg/m2) every 21 days. Tumor assessments were performed every 3
months. Results: As of 8 November 2013, 58 received PoV+ RTX (38 DLBCL; 20 FL), 63 …